NVCR — NOVOCURE LTD
Public company
Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About NOVOCURE LTD (NVCR)
NOVOCURE LTD (NVCR) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $15M. All data sourced from SEC 13F filings.
Tracked investors reporting NVCR
- Steve CohenMar 31, 2026Point72 Asset ManagementShares1.4MValue$14.8M% Portfolio0.02%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares198.2KValue$2.2M% Portfolio0.00%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares91.2KValue$994.2K% Portfolio0.00%
Recent activity
- No recent activity.
Frequently asked questions
- How many institutional investors hold NVCR?
- 3 tracked institutional investors disclosed a position in NVCR (NOVOCURE LTD) in their most recent 13F filing.
- Who is the largest institutional holder of NVCR?
- Steve Cohen, Point72 Asset Management, holds the largest disclosed position in NVCR, valued at $15M.
- Did institutional ownership of NVCR increase or decrease?
- Across recent 13F filings, tracked investors recorded 0 new positions, 0 increased, 0 reduced, and 0 fully exited NVCR.
- Where does this NVCR ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.